Physician
Gastroenterology
Dr. David A. Peura, MD
|
|
Give Review
David Peura practices Gastroenterology. He went to medical school at University of Vermont College of Medicine. He received 2 awards: "CMS Meaningful Use Stage 1 Certification" and "Fellow (AGAF)". David Peura is a published doctor and has 101 publications published. The lastest was: 'Helicobacter pylori: rational management options.'
Publications
- Esomeprazole treatment of frequent heartburn: two randomized, double-blind, placebo-controlled trials.
- Aspirin and proton pump inhibitor combination therapy for prevention of cardiovascular Disease and barrett's esophagus.
- Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux Disease.
- The effects of increasing body mass index on heartburn severity, frequency and Response to treatment with dexlansoprazole or lansoprazole.
- The Prevalence and Incidence of Helicobacter pylori-Associated Peptic Ulcer Disease and Upper Gastrointestinal Bleeding Throughout the World.
- Barrett's esophagus: prevalence and incidence of adenocarcinomas.
- Barrett's esophagus: proton pump inhibitors and chemoprevention II.
- The value of branded proton pump inhibitors: formulary considerations.
- Bleeding after percutaneous endoscopic gastrostomy is linked to serotonin reuptake inhibitors, not aspirin or clopidogrel.
- Review of proton pump inhibitors for the initial treatment of heartburn: Is there a dose ceiling effect?
- Meshed capillary vessels found on narrow-band imaging without optical magnification effectively identifies Colorectal neoplasia: a North American validation of the Jap...
- Long-term quality of life improvement in subjects with healed erosive esophagitis: treatment with lansoprazole.
- Helicobacter pylori-negative gastritis in erosive esophagitis, nonerosive reflux Disease or functional dyspepsia patients.
- Long-term efficacy of lansoprazole in preventing relapse of erosive Reflux esophagitis.
- Lansoprazole 15 mg once daily for 14 days is effective for treatment of frequent heartburn: results of 2 randomized, placebo-controlled, double-blind studies.
- Short- and long-term management of heartburn and other acid-related disorders: development of an algorithm for primary care providers.
- Lansoprazole for long-term maintenance therapy of erosive esophagitis: double-blind comparison with ranitidine.
- Conquering IBS in women: the clinician's pursuit of optimum management strategies.
- Control of gastric acid secretion in health and Disease.
- Helicobacter pylori infection and related gastrointestinal Diseases.
- Proton pump inhibitors: effective first-line treatment for management of dyspepsia.
- The translation of Helicobacter pylori basic research to patient care.
- Heartburn: issues in patient management. A roundtable discussion.
- Prevention of nonsteroidal anti-inflammatory drug-associated gastroIntestinal symptoms and ulcer complications.
- Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials.
- Mandate to modify a medicinal mantra: maybe not yet?
- Helicobacter pylori-Associated Diseases.
- GastroIntestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2-selective inhibitors.
- Managing gastroesophageal reflux Disease - comparative efficacy and outcomes of dexlansoprazole MR.
- Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
- The 12-month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro-oesophageal reflux Disease.
- Changes of Gastric histology in patients with erosive oesophagitis receiving long-term lansoprazole maintenance therapy.
- Stress Ulcer bleeding: hopeful optimism.
- Helicobacter pylori: beyond peptic ulcer Disease.
- The American College of Gastroenterology Bleeding Registry: preliminary findings.
- Ulcerogenesis: integrating the roles of Helicobacter pylori and acid secretion in duodenal Ulcer.
- NasoGastric omeprazole: effects on Gastric pH in critically Ill patients.
- Impact of Helicobacter pylori colonization on immunoreactive epidermal growth factor and transforming growth factor-alpha in Gastric juice. Its potential pathogenetic ...
- The new urea membrane tests: BUT, RUT, or what?
- Stress-related mucosal damage. What to do or not to do.
- Helicobacter pylori and Ulcerogenesis.
- Prostaglandin E2 content in residual Gastric juice reflects endoscopic damage to the Gastric mucosa after naproxen sodium administration.
- The relationship between the content of aggressive and protective components in Gastric juice and endoscopic findings after naproxen sodium and acetaminophen administr...
- Microdose 14C-urea breath test offers diagnosis of Helicobacter pylori in 10 minutes.
- Diagnosis of Helicobacter pylori infection.
- Helicobacter pylori: practical guidelines for diagnosis and treatment.
- Helicobacter pylori: consensus reached: peptic ulcer is on the way to becoming an historic Disease.
- Digestive Health Initiative launches with the Helicobacter pylori Education Program.
- Helicobacter pylori: a diagnostic dilemma and a dilemma of diagnosis.
- Use of trifluoroisopropyl cyanoacrylate polymer (MBR 4197) in patients with bleeding peptic Ulcers of the stomach and duodenum: a randomized controlled study.
- Squamous cell carcinoma of the esophagus associated with peptic duodenal Ulcer.
- Liver injury with alcoholic hyaline after Intestinal resection.
- Is superficial squamous cell carcinoma of the esophagus a Disease of the Western World?
- Hemobilia and liver flukes in a patient from Thailand.
- Triple lumen pylorus--a complication of peptic Ulcer.
- Post-transfusion hepatitis: fatal outcome in two cases with underlying alcoholic liver Disease.
- Cimetidine for prevention and treatment of gastroduodenal mucosal lesions in patients in an intensive care unit.
- AIDS: the scope of the problem and the problem of the 'scope.
- Acyclovir in endoscopically presumed viral esophagitis.
- GastroIntestinal blood loss associated with running a marathon.
- Recognizing, setting therapeutic goals, and selecting therapy for the prevention and treatment of stress-related mucosal damage.
- Stress-related mucosal damage: an overview.
- Running-associated proximal hemorrhagic colitis.
- Evolving perspectives on parenteral H2-receptor antagonist therapy.
- Stress-related mucosal damage.
- Campylobacter pylori, NSAIDS, and smoking: risk factors for peptic ulcer Disease.
- Cycling, a manometric phenomenon due to repetitive episodes of gastroEsophageal reflux and clearance.
- Sigmoid foreign body: enema applicator sheath removed with endoscopic suction.
- Palliative dilation of Esophageal carcinoma.
- Diagnostic laparoscopy: a prospective review of 100 cases.
- Rapid diagnosis of Campylobacter pylori by Gram's stain.
- Controversies, dilemmas, and dialogues. Prophylactic therapy of stress-related mucosal damage: why, which, who, and so what?
- Topical therapy for the control of gastroIntestinal bleeding.
- Small bile duct abnormalities in sarcoidosis.
- Sucralfate used as adjunctive therapy in patients with severe erosive peptic esophagitis resulting from gastroEsophageal reflux.
- Campylobacter (Helicobacter) pylori. Is peptic Disease a bacterial infection?
- Gastroduodenal mucus gel thickness in patients with Helicobacter pylori: a method for assessment of biopsy specimens.
- Stress-related mucosal damage: review of drug therapy.
- Effect of cimetidine on marathon-associated gastroIntestinal symptoms and bleeding.
- Mucolytic effects of Helicobacter pylori.
- Palliative treatment of Esophageal carcinoma using Esophageal dilation and prosthesis.
- Esophageal prosthesis in Cancer.
- Clinical trial: lansoprazole 15 or 30 mg once daily vs. placebo for treatment of frequent nighttime heartburn in self-treating subjects.
- The clinical safety of long-term lansoprazole for the maintenance of healed erosive oesophagitis.
- Comparison of Prilosec OTC (omeprazole magnesium 20.6 mg) to placebo for 14 days in the treatment of frequent heartburn.
- GastroIntestinal disorders are among the most common disorders encountered in the United States and Europe.
- Chairmen''s summary: dichotomies and directions in acid-related disorders.
- Prevalence of Gastric myoelectrical abnormalities in patients with nonulcer dyspepsia and H. pylori infection: resolution after H. pylori eradication.
- Salivary and gastric epidermal growth factor in patients with Zollinger-Ellison Syndrome: its protective potential.
- Helicobacter pylori-related Disease: guidelines for testing and treatment.
- The problem of Helicobacter pylori-negative idiopathic ulcer Disease.
- Usefulness of serological IgG antibody determinations for confirming eradication of Helicobacter pylori infection.
- H. pylori infection and GI Disease: what critical care physicians need to know. Who should be tested for H. pylori? When is treatment needed?
- Practical advice on eradicating Helicobacter pylori infection.
- Recognizing peptic ulcer Disease. Keys to clinical and laboratory diagnosis.
- Scope and consequences of peptic ulcer Disease. How important is asymptomatic Helicobacter pylori infection?
- Helicobacter pylori: rational management options.
- Serious gastroIntestinal events from low dose analgesic use.
- Self-selection and use patterns of over-the-counter omeprazole for frequent heartburn.
- Efficacy of omeprazole for the treatment of symptomatic acid reflux Disease without esophagitis.
Schools
University of Vermont College of Medicine
Letterman Army Med Center
Walter Reed Army Med Center
Procedures Preformed
- Colonoscopy, Proctosigmoidoscopy, and Sigmoidoscopy
- Endoscopy (Esophagus, Stomach, Small Intestine)
- Liver Biopsy
Conditions Treated
- Abdominal Pain
- Anemia
- Benign Neoplasm of the Digestive System
- Biliary Atresia
- View All
Doctors Specialties
- Gastroenterology
Accepted Insurances
- Choice Plus POS II
- Amerigroup (Wellpoint)
- Pathway X Tier Hosp HealthKeepers DirectAccess VA
- HealthKeepers HMO
- KeyCare PPO
- Blue Card PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- CoreSource
- Southern Health PPO
- Coventry Health Care of Virginia HMO
- Emblem Health
- First Health (Coventry Health Care) PPO
- Choice Care PPO
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Pyramid Life
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- CMS Meaningful Use Stage 1 Certification
- Fellow (AGAF)
Education
-
University of Vermont College of Medicine
Hospital
-
University of Virginia Medical Center
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1306981717 |
| Last Name Of The Provider | PEURA |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
Dr. Curtis K. Argo, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Wissam A. Bleibel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brian W. Behm, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Abdullah Al-Osaimi, MD |
|
|
Dr. Christopher Hammerle, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jenny L. Smith, MD |
|
Dr. Steven M. Cohn, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Patrick G. Northup, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amy E. Doran, MD |
|
|
Dr. David H. Balaban, MD |
|
|
Dr. Nitin K. Ahuja, MD |
|
|
Dr. Robert A. Lockwood, MD |